(Q44256487)

1 December 2017

title

Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection (English)

1 reference

1 December 2017

0 references

4

1 reference

1 December 2017

Guttner Y

1

1 reference

1 December 2017

Windsor HM

series ordinal

2

1 reference

1 December 2017

Viiala CH

series ordinal

3

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Alimentary Pharmacology & Therapeutics

1 December 2017

published in

1 reference

1 December 2017

volume

17

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

125-129

1 reference

Identification of the bactericidal domain of lactoferrin

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

Bacteriostasis of Escherichia coli by bovine lactoferrin, transferrin and immunoglobulins (IgG1, IgG2, IgM) acting alone or in combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

Novel therapies for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

Human lactoferrin: a novel therapeutic with broad spectrum potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when human lactoferrin is present

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

The13C-urea breath test as a predictor of intragastric bacterial load and severity ofHelicobacter pylorigastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01395.X

Synergic antistaphylococcal properties of lactoferrin and lysozyme

21 January 2018

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1046/J.1365-2036.2003.01395.X

Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1046/J.1365-2036.2003.01395.X

Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1046/J.1365-2036.2003.01395.X

Potent Antibacterial Peptides Generated by Pepsin Digestion of Bovine Lactoferrin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1046/J.1365-2036.2003.01395.X

Gastric juice levels of lactoferrin and Helicobacter pylori infection

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1046/J.1365-2036.2003.01395.X

Isolation of an Iron-Containing Red Protein from Human Milk

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1046/J.1365-2036.2003.01395.X

Identifiers

DOI

10.1046/J.1365-2036.2003.01395.X

1 reference

1 December 2017

1 reference